Immunology and Allergology Unit, Department of Mother-Child, Urological Science, Sapienza University of Rome, 00161 Rome, Italy.
Pediatric Clinic, Department of Pediatrics, Fondazione IRCSS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy.
Nutrients. 2021 Apr 16;13(4):1315. doi: 10.3390/nu13041315.
Probiotics may prevent the allergic response development due to their anti-inflammatory and immunomodulatory effects. The aim of this study is to determine if the prophylactic treatment with a mixture of subsp. BB12 and L3 would reduce symptoms and need for drug use in children with allergic rhinitis (AR).
The study included 250 children aged from 6 to 17 years, affected by AR. Patients were randomly assigned to the intervention group (150) or to the placebo group (100). Patients in the intervention group, in addition to conventional therapy (local corticosteroids and/or oral antihistamines), were treated in the 3 months preceding the onset of symptoms related to the presence of the allergen to which the children were most sensitized, with a daily oral administration of a probiotic mixture containing the subsp. BB12 DSM 15954 and the L3 LMG P-27496 strain. We used Nasal Symptoms Score (NSS) to evaluate AR severity before and after the treatment with probiotics or placebo.
the patients in the intervention group had a significant reduction in their NSS after probiotic treatment (-value = 2.2 × 10. Moreover, for the same group of patients, we obtained a significant reduction in the intake of pharmacological therapy. In particular, we obtained a reduction in the use of oral antihistamines (-value = 2.2 × 10), local corticosteroids (-value = 2.2 × 10), and of both drugs (-value 1.5 × 10).
When administered as a prophylactic treatment, a mixture of BB12 and L3 statistically decreased signs and symptoms of AR and reduced significantly the need of conventional therapy.
益生菌通过其抗炎和免疫调节作用可能预防过敏反应的发展。本研究旨在确定预防性使用 subsp. BB12 和 L3 的混合物是否会减轻过敏性鼻炎 (AR) 患儿的症状和药物使用需求。
该研究纳入了 250 名年龄在 6 至 17 岁之间、患有 AR 的儿童。患者被随机分配到干预组（150 名）或安慰剂组（100 名）。干预组患者除了接受常规治疗（局部皮质类固醇和/或口服抗组胺药）外，还在与儿童最敏感的过敏原相关症状出现前的 3 个月内，每天口服含有 subsp. BB12 DSM 15954 和 L3 LMG P-27496 菌株的益生菌混合物进行治疗。我们使用鼻症状评分（NSS）来评估益生菌或安慰剂治疗前后 AR 的严重程度。
干预组患者在益生菌治疗后 NSS 显著降低（-值 = 2.2×10。此外，对于同一组患者，我们还获得了药物治疗摄入的显著减少。特别是，我们减少了口服抗组胺药（-值 = 2.2×10）、局部皮质类固醇（-值 = 2.2×10）和两种药物的使用（-值 1.5×10）。
作为预防性治疗，BB12 和 L3 的混合物可统计学上减轻 AR 的体征和症状，并显著减少常规治疗的需求。
